PHARMACOTHERAPY FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: HEART–LIVER CO-MANAGEMENT

Xiao-Dong Zhou, Jeffrey V Lazarus, Chayakrit Krittanawong, Giovanni Targher, Christopher D Byrne, Zobair M Younossi, Frank Tacke, Qin-Fen Chen, Christos S Mantzaros, Herbert Tilg, Wajahat Z Mehal, Laurence S Sperling, Gregory Y H Lip, Norbert Stefan,

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects a significant portion of the adult population, with many cases progressing to MASH, which poses serious health risks including cirrhosis and hepatocellular carcinoma. The review emphasizes the need for a collaborative approach between hepatologists and cardiologists to effectively manage both liver and cardiovascular health. It evaluates various pharmacological strategies, including metabolic-targeted therapies and liver-targeted therapies, while also addressing the challenges faced in current clinical practices and the need for further research into cardiovascular safety.